UBS Group AG lowered its holdings in shares of Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI – Free Report) by 69.2% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 738,927 shares of the company’s stock after selling 1,660,285 shares during the quarter. UBS Group AG’s holdings in Maravai LifeSciences were worth $2,402,000 as of its most recent filing with the Securities & Exchange Commission.
Other large investors have also recently made changes to their positions in the company. Sprott Inc. purchased a new stake in shares of Maravai LifeSciences during the 3rd quarter valued at about $29,000. Quantessence Capital LLC purchased a new position in Maravai LifeSciences in the third quarter worth about $31,000. Abel Hall LLC bought a new stake in Maravai LifeSciences during the third quarter worth approximately $33,000. CIBC Bancorp USA Inc. bought a new stake in Maravai LifeSciences during the third quarter worth approximately $33,000. Finally, Ballentine Partners LLC purchased a new stake in Maravai LifeSciences during the third quarter valued at approximately $37,000. 50.25% of the stock is currently owned by institutional investors.
Wall Street Analysts Forecast Growth
Several equities research analysts have recently issued reports on MRVI shares. Weiss Ratings lowered Maravai LifeSciences from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Wednesday, May 13th. Wall Street Zen raised Maravai LifeSciences from a “hold” rating to a “buy” rating in a research report on Saturday. Wells Fargo & Company increased their price target on Maravai LifeSciences from $4.50 to $5.50 and gave the company an “overweight” rating in a report on Friday, May 8th. Finally, Deutsche Bank Aktiengesellschaft restated a “buy” rating and issued a $6.00 price target on shares of Maravai LifeSciences in a research report on Friday, May 8th. Three analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $5.50.
Maravai LifeSciences Trading Down 0.5%
MRVI opened at $4.38 on Wednesday. The company has a debt-to-equity ratio of 0.72, a quick ratio of 4.96 and a current ratio of 5.91. The stock’s 50 day moving average price is $3.57 and its 200-day moving average price is $3.50. Maravai LifeSciences Holdings, Inc. has a one year low of $1.99 and a one year high of $4.99. The stock has a market cap of $1.13 billion, a price-to-earnings ratio of -6.17 and a beta of 0.62.
Maravai LifeSciences (NASDAQ:MRVI – Get Free Report) last posted its quarterly earnings data on Thursday, May 7th. The company reported $0.01 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.05) by $0.06. Maravai LifeSciences had a negative return on equity of 17.87% and a negative net margin of 51.07%.The company had revenue of $65.84 million during the quarter, compared to analysts’ expectations of $53.00 million. On average, equities analysts forecast that Maravai LifeSciences Holdings, Inc. will post -0.26 EPS for the current year.
Maravai LifeSciences Company Profile
Maravai LifeSciences Holdings, Inc (NASDAQ: MRVI) is a life sciences company specializing in the development and supply of critical reagents and services for the development and manufacture of biologic therapies. The company’s offerings support a range of applications in genomics, molecular diagnostics, vaccine development and next-generation sequencing. Maravai’s platforms address key challenges in nucleic acid production, protein detection, epigenetic analysis and reagent quality across the biopharmaceutical industry.
Through its product portfolio, which includes proprietary mRNA capping reagents, lipid nanoparticle delivery systems, synthetic oligonucleotides and high-precision assay kits, Maravai enables customers to accelerate research and streamline manufacturing workflows.
Featured Articles
- Five stocks we like better than Maravai LifeSciences
- Banks Are Buying Back Stock Hand Over Fist, Including These 3 Names
- 2 Aluminum Stocks Poised for Big Tariff-Related Gains
- AutoZone’s Pullback Sets Up a Long-Term Buying Opportunity
- AST SpaceMobile’s June Launch Plan Puts Its 2026 Satellite Goal Back in Focus
Want to see what other hedge funds are holding MRVI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI – Free Report).
Receive News & Ratings for Maravai LifeSciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Maravai LifeSciences and related companies with MarketBeat.com's FREE daily email newsletter.
